Hepatitis C therapeutics: current status and emerging strategies

Chronic infection with hepatitis C virus (HCV) is an emerging global epidemic. The development of effective HCV antiviral therapeutics continues to be a daunting challenge owing to the absence of adequate animal models and tissue-culture systems for analysis and propagation of the virus. Despite the...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Drug discovery Vol. 1; no. 11; pp. 867 - 881
Main Authors Sonenberg, Nahum, Tan, Seng-Lai, Pause, Arnim, Shi, Yuguang
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.11.2002
Subjects
Animals
Antiviral agents
Base Sequence
Diagnosis
Dosage and administration
Drug therapy
Gene expression
Hepatitis C
Hepatitis C virus
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - genetics
Hepatitis C, Chronic - metabolism
Humans
Molecular Sequence Data
Physiological aspects
Risk factors
Technology, Pharmaceutical - methods
Viral Hepatitis Vaccines - chemistry
Viral Hepatitis Vaccines - genetics
Viral Hepatitis Vaccines - therapeutic use
United States
Online AccessGet full text

Cover

More Information
Summary:Chronic infection with hepatitis C virus (HCV) is an emerging global epidemic. The development of effective HCV antiviral therapeutics continues to be a daunting challenge owing to the absence of adequate animal models and tissue-culture systems for analysis and propagation of the virus. Despite these obstacles, inhibitors of the replicative elements of HCV, immune modulators and non-specific hepatoprotective agents are being pursued and exciting progress has been made. Successful therapeutic intervention of HCV will probably require combination approaches and new approaches, including host drug discovery targets.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1474-1776
1474-1784
1474-1784
DOI:10.1038/nrd937